55 Kenosia Avenue
Danbury, CT 06810
Phone: 203.744.0100
Toll Free: 1.800.999.6673

Pyruvate Kinase Deficiency

The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.

Copyright 1987, 1988, 1990, 1998, 2005

Synonyms of Pyruvate Kinase Deficiency

Disorder Subdivisions

General Discussion

Red cell pyruvate kinase deficiency is a hereditary blood disorder characterized by a deficiency of the enzyme pyruvate kinase. Physical findings associated with the disorder may include reduced levels of oxygen-carrying hemoglobulin in the blood due to premature destruction of red blood cells (hemolytic anemia); abnormally increased levels of bilirubin in the blood (hyperbilirubinemia); abnormal enlargement of the spleen (splenomegaly); and/or other abnormalities. Pyruvate kinase deficiency is inherited as an autosomal recessive genetic trait. It is one of a group of diseases known as hereditary nonspherocytic hemolytic anemias. (Nonspherocytic refers to the fact that the red blood cells do not assume a spherical shape, as they do with some blood disorders.


Pyruvate kinase deficiency is characterized by hemolytic anemia. An excess of young red blood cells (reticulocytes) usually occurs. The anemia is chronic and may vary from mild to severe. Enlargement of the spleen (splenomegaly) may occur, and gallstones may sometimes develop. After infections, the anemia tends to become more severe. In rare cases, leg ulcers may develop.


Pyruvate kinase deficiency is inherited in an autosomal-recessive manner. It is caused by mutations of the PKLR gene, the gene that encodes the liver and red cell type of pyruvate kinase. The gene is located on chromosome 1 (1q21).

Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes are numbered from 1 through 22, and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated p and a long arm designated q. Chromosomes are further sub-divided into many bands that are numbered. For example, chromosome 1q21 refers to band 21 on the long arm of chromosome 1. The numbered bands specify the location of the thousands of genes that are present on each chromosome.

Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.

Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.

All individuals carry a few abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.

Affected Populations

The incidence of pyruvate kinase deficiency is less than 1% of the population. Males and females are affected in equal numbers. Most affected persons identified thus far have been of European origin.

Related Disorders

Hereditary nonspherocytic hemolytic anemias are thought to be a heterogeneous group of disorders characterized by red blood cell defects situated entirely within these cells (intrinsic). The abnormal spheroid shaped red cells known as spherocytes are not present in this type of hemolytic anemia. Symptoms of hereditary nonspherocytic hemolytic anemia include moderate anemia, intermittent yellowing of the skin (jaundice) and occasionally an enlarged spleen (splenomegaly). (For more information, choose "nonspherocytic anemia" as your search term in the Rare Disease Database.)

Hereditary spherocytic hemolytic anemia (hereditary spherocytosis) is characterized by the presence of red blood cells with a greater than normal thickness giving them a spherical shape (spherocytes). Excessive red blood cell destruction occurs which causes anemia, jaundice and a feeling of discomfort (malaise). The severity of the disorder varies greatly among patients. (For more information on this disorder, choose "spherocytic anemia" as your search term in the Rare Disease Database.)

Glucose-6-phosphatase dehydrogenase deficiency (G-6-PD) may be caused by sensitivity to certain drugs in some patients. It is usually inherited through sex-linked genes. Symptoms are caused by a deficiency of the enzyme glucose-6- phosphate dehydrogenase. Separation of hemoglobin from the red blood cells (hemolysis) may be triggered in older red blood cells by exposure to certain drugs or other substances that produce peroxide and cause oxidation of hemoglobin in the red blood cells. These substances include the drugs primaquine, aspirin, sulfonamides, nitrofurans, phenacetin, naphthalene, some vitamin K derivatives, and fava beans. Acute viral or bacterial infections, or diabetic acidosis may also precipitate hemolysis. Anemia, jaundice and the presence of immature red blood cells (reticulocytes) may develop. Chronic inborn hemolysis in the absence of drugs may occur in some persons of European heredity.

Standard Therapies

A physical examination that reveals an enlarged spleen in the presence of jaundice is usually sufficient to trigger a call for more definitive tests. A complete blood count, differential blood counts, and reticulocyte counts may be undertaken. Tests for the presence of bile salts (bilirubin) are used to determine whether the gall bladder is involved. DNA analysis may be ordered to confirm the diagnosis.

Mild cases require no treatment. More severe disease is usually treated with blood transfusions. Surgical removal of the spleen (splenectomy) may also be needed. With small children, this is delayed as long as possible to allow the immune system to mature. Other treatment is symptomatic and supportive.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:

Organizations related to Pyruvate Kinase Deficiency


Beutler E. Pyruvate Kinase Deficiency. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:496-97.

Scriver CR, Beaudet AL, Sly WS, et al., eds. The Metabolic Molecular Basis of Inherited Disease. 8th ed. McGraw-Hill Companies. New York, NY; 2001:4638-44.

Bennett JC, Plum F., eds. Cecil Textbook of Medicine. 20th ed. W.B. Saunders Co., Philadelphia, PA; 1996:859.

Aizawa S, Kohdera U, Hiramoto M, et al. Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency. Am J Hematol. 2003;74:68-72.

Van Rijk R, van Solinge WW, Nerlov C, et al. Disruption of a novel regulatory element in the erythroid-specific promoter of the human PKLR gene causes severe pyruvate kinase deficiency. Bllod. 2003;101:1596-602.

Watanabe Y, Miyauchi K, Horiuchi A, et al. Concomitant laparoscopic splenectomy and cholecystectomy as an effective and minimally invasive treatment of pyruvate kinase deficiency with gallstones. Surg Endosc. 2002;16:1495.

Valentini G, Chiarelli LR, Fortin R, et al. Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia. J Biol Chem. 2002;277:23807-14.

Zanella A, Bianchi P, Fermo E, et al. Molecular characterization of the PK-LR gene in sixteen pyruvate kinase-deficient patients. Br J Haematol. 2001;113:43-48.

Tanphaichitr VS, Suvatte V, Issaragrisil S, et al. Successful bone marrow transplantation in a child with red blood cell pyruvate kinase deficiency. Bone Marrow Transplant. 2000;26:689-90.

Zanella A, Bianchi P. Red cell pyruvate kinase deficiency: from genetics to clinical manifestations. Baillieres Best Pract Res Clin Haematol. 2000;13:57-81.

McKusick VA, ed. Online Mendelian Inheritance In Man (OMIM). The Johns Hopkins University. Pyruvate Kinase Deficiency of Erythrocyte. Entry Number; 266200: Last Edit Date; 1/21/2005.

McKusick VA, ed. Online Mendelian Inheritance In Man (OMIM). The Johns Hopkins University. Pyruvate Kinase 3; PK3. Entry Number; 179050: Last Edit Date; 7/17/2003.

Stewart DR. Pyruvate kinase deficiency. Medical Encyclopedia. MedlinePlus. Update Date: 7/26/2004. 2pp.

Yaish HM. Pyruvate Kinase Deficiency. emedicine. Last Updated: December 9, 2004. 11pp.

Frye RE, DeLaughery TG. Pyruvate Kinase Deficiency. emedicine. Last Updated. February 4, 2005. 12pp.

Max-Audit I. Pyruvate kinase deficiency. Orphanet. December 2001. 1p.

Report last updated: 2008/03/31 00:00:00 GMT+0